An Initial Clinical Trial of CTS-2090
Latest Information Update: 16 Aug 2019
At a glance
- Drugs CTS 2090 (Primary)
- Indications Inflammation
- Focus Adverse reactions
Most Recent Events
- 06 Aug 2019 According to a Conatus Pharmaceuticals media release, company was implementing a restructuring plan in order to extend its resources, which included reducing staff and suspending development of its inflammasome disease candidate, CTS-2090.
- 06 Aug 2019 Status changed from planning to suspended, according to a Conatus Pharmaceuticals media release.
- 15 Mar 2019 New trial record